Department of Vascular Surgery, University of Florence, Florence, Italy.
Department of Vascular Surgery, University of Florence, Florence, Italy.
J Vasc Surg. 2021 Jul;74(1):90-96.e2. doi: 10.1016/j.jvs.2020.11.042. Epub 2020 Dec 17.
We tested the outcomes with the use of the enhanced recovery after surgery protocol in patients who had undergone open abdominal aortic aneurysm (AAA) repair (enhanced recovery after vascular surgery [ERAVS] protocol). We compared them with those obtained for patients who had undergone endovascular aneurysm repair (EVAR) and for a historical control group of standard open AAA repair in a prospective, single-center pilot study.
From June to December 2019, all patients who were candidates for open AAA repair at our department were enrolled in the ERAVS protocol (ERAVS group; 17 patients). During the same period, 18 patients had undergone EVAR (EVAR group). The historical control group of standard open AAA repair included 32 patients who had undergone surgery during the 6 months before the study period (standard protocol open repair [OR] group). The three groups were compared on an "on-treatment" basis (prospectively for the ERAVS and EVAR groups and retrospectively for the OR group) in terms of the time to discharge (TTD), interval to the resumption of oral intake, time to ambulation, resumption of bowel function, and postoperative pain. Comparisons were performed using the one-way analysis of variance test, Tukey post hoc test for quantitative data, and χ test for qualitative data.
The ERAVS protocol was successfully applied for all but one patient (feasibility rate, 94%). The mean TTD was 5.1 days in the ERAVS group, 3.5 days in the EVAR group, and 8.4 days in the OR group [P < .001; F(2,64) = 11.3], with a significant difference between the OR and ERAVS and EVAR groups (P = .1 and P < .001, respectively) but not between the EVAR and ERAVS groups (P = .4). The ERAVS group had intervals to the resumption of oral intake and ambulation similar to those of the EVAR group. In contrast, these were significantly longer for the OR group. The mean time to the resumption of bowel function was similar in the ERAVS and OR groups (2.6 and 2.9 days, respectively; P = .6). In the ERAVS group, the mean value of the maximum referred pain using the numeric rating scale was 3.75 (range, 1-6). The corresponding values for the EVAR and OR groups were 2.6 (range, 0-6) and 4.9 [range, 1-8; F(2,62) = 15.4; P < .001]. The post hoc test showed a significant difference between the OR group and the ERAVS and EVAR group (P = .01 and P < .001, respectively) but not between the ERAVS and EVAR groups (P = .07).
In our early experience, the ERAVS protocol appeared to be effective in reducing the TTD and improving the postoperative outcomes compared with the OR group, without significant differences compared with the EVAR group.
我们测试了采用术后强化康复方案(增强血管手术后康复方案 [ERAVS])对接受开放式腹主动脉瘤(AAA)修复的患者的治疗结果。我们将这些结果与接受血管内动脉瘤修复(EVAR)的患者以及前瞻性单中心试点研究中标准开放式 AAA 修复的历史对照组进行比较。
2019 年 6 月至 12 月,我们科室所有符合开放式 AAA 修复条件的患者均被纳入 ERAVS 方案(ERAVS 组;17 例)。同期,18 例患者接受了 EVAR(EVAR 组)。标准开放式 AAA 修复的历史对照组包括在研究期间前 6 个月接受手术的 32 例患者(标准方案开放式修复 [OR] 组)。三组均采用“治疗性”(ERAVS 和 EVAR 组前瞻性,OR 组回顾性)比较,比较指标为出院时间(TTD)、恢复口服摄入时间、开始行走时间、恢复肠道功能时间和术后疼痛。采用单因素方差分析、Tukey 事后检验进行定量数据比较,采用 χ 检验进行定性数据比较。
ERAVS 方案除 1 例患者外均成功实施(可行性率为 94%)。ERAVS 组的平均 TTD 为 5.1 天,EVAR 组为 3.5 天,OR 组为 8.4 天[P <.001;F(2,64) = 11.3],OR 组与 ERAVS 组和 EVAR 组之间存在显著差异(P =.1 和 P <.001),但 EVAR 组与 ERAVS 组之间无显著差异(P =.4)。ERAVS 组恢复口服摄入和开始行走的时间与 EVAR 组相似。相比之下,OR 组的时间明显更长。ERAVS 组和 OR 组的肠道功能恢复平均时间相似(分别为 2.6 天和 2.9 天;P =.6)。ERAVS 组使用数字评分量表测量的最大疼痛评分平均值为 3.75(范围,1-6)。EVAR 组和 OR 组的相应值分别为 2.6(范围,0-6)和 4.9 [范围,1-8;F(2,62) = 15.4;P <.001]。事后检验显示,OR 组与 ERAVS 组和 EVAR 组之间存在显著差异(P =.01 和 P <.001),但 ERAVS 组与 EVAR 组之间无显著差异(P =.07)。
在我们的初步经验中,与 OR 组相比,ERAVS 方案似乎能有效缩短 TTD 并改善术后结局,与 EVAR 组相比无显著差异。